Analyst Sets 34% Upside Target After 2.1% Intraday Gain for Sarepta Therapeutics
SRPT•An analyst sets a 34% upside target for Sarepta Therapeutics, forecasting a sustained rally in the stock. The bullish call on July 9 coincided with a 2.1% intraday share gain, signaling increased investor confidence.
1. Analyst Upside Projection
On July 9, an equity analyst initiated coverage on Sarepta Therapeutics with a target price implying 34% upside and forecasted a sustained rally driven by upcoming catalysts in the company’s development pipeline.
2. Share Price Reaction
SRPT shares climbed 2.1% intraday following the publication of the report, reflecting immediate investor response to the bullish projection and elevated optimism around future stock performance.
